Evidence map›Paper›PMID 26141741›Full record

ReviewWiener medizinische Wochenschrift (1946)2015

[Depression in cancer patients].

Barbara Sperner-Unterweger

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Barbara Sperner-UnterwegerDepartment für Psychiatrie und Psychotherapie, Medizinische Universität Innsbruck, Anichstrasse 35, 6020, Innsbruck, Österreich, barbara.sperner-unterweger@i-med.ac.at.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer patients often suffer from major depression or depressive syndromes. Although it is well known that depressive symptoms can appear at any time during the course of an oncological disease, certain periods for instance time after diagnosis carry a higher risk. Reported prevalence rates differ widely (up to 60%), reflecting also diagnostic difficulties. Oncologists recognize depression in their patients only in 15 to 50% and the percentage of patients who receive adequate therapy is even lower. Consequently, this leads to a reduced quality of life. Furthermore, impaired compliance/adherence and consequently a poorer prognosis of the oncological disease are discussed in this context. It should be also emphasized, that concomitant depression increases the risk of suicide in cancer patients. Although the number of clinical trials using either psychotherapy or antidepressant medication for the therapy of depression in cancer patients is limited, good therapeutic options are available.

Indexed as

Antidepressive AgentsComorbidityCooperative BehaviorCross-Sectional StudiesDepressive DisorderHumansInterdisciplinary CommunicationMajor Depressive DisorderNeoplasmsPsychotherapyQuality of LifeRisk FactorsSuicideSuicide PreventionAntidepressive Agents

Identifiers

PMID26141741
OpenAlexW2460402436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.